Existing and future therapeutic options for hepatitis C virus infection.

Maria Bretner

doi:10.18388/abp.2005_3487

Existing and future therapeutic options for hepatitis C virus infection.

Maria Bretner Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warszawa, Poland. majka@ibb.waw.pl;

DOI: https://doi.org/10.18388/abp.2005_3487

Abstract

Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver failure worldwide. Chronic hepatitis C virus infection is treated with interferon-a (IFN-alpha), pegylated interferon-alpha (PEG-IFNalpha) alone or in combination with ribavirin; however, a significant fraction of patients either fail to respond or relapse after cessation of therapy. Efforts to identify and develop highly specific and potent HCV inhibitors have intensified recently. Each of the virally encoded replication enzymes has been a focus of studies as well as viral receptors and the host immune system. This review summarizes recent progress in the search for novel anti-HCV agents.

Published

2005-03-31

Issue

Vol. 52 No. 1 (2005)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.